Showing results (1-10 of 13) with videos related to
Sort By:
Pageof 2
Patient Preference and Adherence|March 14, 2019
Mode of injection and treatment adherence: results of a survey characterizing the perspectives of health care providers and US women 18-45 years oldDavid L Gandell, E Jay Bienen, Jennifer GudemanExpert Opinion on Drug Safety|June 19, 2012
Clinical overview of the seizure risk of dalfampridineSheryl R Haut, E Jay Bienen, Aaron MillerPain Practice : the Official Journal of World Institute of Pain|July 7, 2010
Assessing dimensionality and responsiveness of outcomes measures for patients with low back painJosh Cleland, Rabya Gillani, E Jay Bienen, et al.Clinical Therapeutics|April 14, 2012
The safety profile of dalfampridine extended release in multiple sclerosis clinical trialsDavid R Cornblath, E Jay Bienen, Andrew R BlightJournal of Pain Research|May 1, 2015
A cross-sectional study examining the psychometric properties of the painDETECT measure in neuropathic painJoseph C Cappelleri, Vijaya Koduru, E Jay Bienen, et al.Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation|August 4, 2016
Mapping painDETECT, a neuropathic pain screening tool, to the EuroQol (EQ-5D-3L)Joseph C Cappelleri, Vijaya Koduru, E Jay Bienen, et al.Patient Related Outcome Measures|July 28, 2016
Characterizing neuropathic pain profiles: enriching interpretation of painDETECTJoseph C Cappelleri, Vijaya Koduru, E Jay Bienen, et al.Clinicoeconomics and Outcomes Research : CEOR|August 25, 2016
Characterizing individual painDETECT symptoms by average pain severityAlesia Sadosky, Vijaya Koduru, E Jay Bienen, et al.Clinicoeconomics and Outcomes Research : CEOR|November 15, 2014
Measurement properties of painDETECT by average pain severityJoseph C Cappelleri, E Jay Bienen, Vijaya Koduru, et al.Journal of Medical Economics|October 19, 2010
Contribution of intangible costs to the economic burden of multiple sclerosisAnnette Wundes, Theodore Brown, E Jay Bienen, et al.Pageof 2